Chime Financial (CHYM) Q3 2026 Earnings Call Transcript

Chime reported Q3 revenue of $718 million, up 32% year over year, adjusted EBITDA of $137 million at a 19% margin, and $44 million of GAAP net income for a third consecutive profitable quarter. Active members grew 20% to 10.9 million, while gross margin reached 90%; management raised Q4 revenue guidance to $757 million–$767 million and expects full-year 2026 revenue of $2.792 billion–$2.802 billion. First-time loans contributed to a sequential increase in the overall loss rate to 1.1%, and the planned Stride Bank acquisition remains subject to regulatory approval, which management expects in the first half of 2027.

Analysis

The key valuation question is whether CHYM is shifting from a growth fintech into a sustainably higher-earnings platform—or whether the quarter’s unusually strong operating leverage is partly a favorable comp and mix effect. Prime-driven credit adoption can lift monetization, but it also changes the risk mix: first-time borrowers are less seasoned, so growth in originations may precede any proof that repeat-borrower performance offsets early losses. Treat management’s nearly 10x LTV/CAC and lower repeat-loan losses as claims to validate against cohort disclosures, not as mature-cycle economics.

Over the next 1–3 months, the Q4 outlook is the test of whether faster growth and margin expansion persist through higher product investment and seasonal operating costs. Over 6–18 months, Stride could improve funding economics and product availability, but the expected synergies depend on regulatory approval, account migration and execution; the transaction is not yet a bank-cost advantage. The stated sub-$10bn asset posture may also constrain balance-sheet growth if liquidity products scale faster than anticipated, potentially requiring asset sales or tighter origination.

The risk/reward is asymmetric around credit quality and execution rather than member growth alone. A low-cost, deposit-underwritten model could pressure standalone liquidity lenders such as DAVE if CHYM’s pricing advantage is real, but the comparison is management’s characterization and needs independent evidence. No valuation or post-earnings price data is supplied, so avoid assuming the positive operating update is underpriced.

Key Decisions for Investors

• CHYM: Consider a staged long only after the first two post-earnings sessions, if the market holds the initial reaction and Q4 guidance remains intact. Add only on confirmation from the next report that revenue growth is translating into durable transaction profit; do not anchor on the quarter’s 62% incremental adjusted EBITDA margin.
• Risk controls: Reassess the long if management cuts the Q4 outlook, MyPay losses move persistently above its stated 0.9%–1.2% operating band, or Instant Loan losses rise without repeat-borrower cohorts improving. Verify cohort-level delinquency/loss data and credit mix in filings.
• Stride is a catalyst watch, not a current synergy trade: monitor regulatory approval, closing timing, integration costs and evidence of deposit migration. Any delay beyond the expected first half of 2027, or revised synergy assumptions, weakens the medium-term earnings case.
• DAVE: Do not initiate a short solely on CHYM’s competitive claims. Revisit a relative-value short only if independent disclosures show CHYM taking share or forcing lower pricing while DAVE’s unit economics deteriorate; otherwise business-model differences make the pair fragile.